Cardiovascular Inflammation Reduction TrialStatus: open
Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients.
Treatment for Coronary Artery Disease
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH). This trial is held at the Moorer Building which is located on the University Hospital's campus.
SponsorsThis trial is sponsored by National Heart Lung and Blood Institute.
Interested in Clinical Trial?
Providers Associated With This Trial
- Ghulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine